VRDN · Viridian Therapeutics, Inc.\DE

Track VRDN — free

$19.00 -0.40 (-2.06%)

Russell 2000 member Rebalance outlook locked

Market Cap

$2.32B

113.29M

Volume · Oct 5 2.65M Avg daily vol (3M) 1.71M

Up next

Latest filing: 10-Q

filed Aug 6, 2026

Q1 2024 earnings call transcript

call held May 8, 2024

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$71.13M

Trailing 12 months

Net income (TTM)

−$386.97M

Trailing 12 months

Revenue growth YoY

+278.7%

Year over year

Operating margin

-569.7%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-14.4%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+27.8%

Year over year · more shares

Price change (1Y)

-8.6%

Trailing year

Short interest

17.2%

Latest settlement · 15.7 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Sell Momentum Neutral Sentiment Neutral Fundamentals Weak Quant / Vol Very High

Market backdrop VIX 15.3 · calm Equity put/call 0.58

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −15%

below

Price vs 50-day avg −12%

below

RSI (14) 36

neutral

MACD trend Negative

52-week position 30%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Neutral

1-month return −16%

trailing

6-month return +31%

trailing

YTD return −38%

this year

Relative strength +19%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $22 › 200d $23 — 200d above 50d

Institutional flow Distributing

2 of 217 funds reported for Sep 30 · net -30.0K sh shares

Insider flow Distributing

Net -$348.2K over 90 days · 100% sells

Short interest Falling

17.18% of float · ▼ -0.2% MoM · 15.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

217 holders — mid 3-yr range

Squeeze score 66

elevated · 0–100

Fundamentals

Weak

Revenue growth −12%

Y/Y

EPS growth −31%

Y/Y

Free cash flow $-276.9M

Balance sheet $79.0M

net cash

Quant / Vol

risk profile

Very High

Volatility 71%

annualized · 1-yr

Max drawdown −61%

past year

ATR 4.8%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell

3 · 4 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−15% Bearish

Price vs 50-day avg

−12% Bearish

RSI (14)

36 Neutral

MACD trend

Negative Bearish

52-week position

30% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $22 › 200d $23 — 200d above 50d

Institutional flow Distributing

2 of 217 funds reported for Sep 30 · net -30.0K sh shares

Insider flow Distributing

Net -$348.2K over 90 days · 100% sells

Short interest Falling

17.18% of float · ▼ -0.2% MoM · 15.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

217 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $13 Now $19 · 30% Range high $34

vs 200-day avg -15% vs 50-day avg -12%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
Core prescribing physicians	2,000	as of July 31, 2026	—
Core prescribing physicians engaged	95%	as of July 31, 2026	—
Shares of common stock outstanding on an as-converted basis	125,349,092	as of June 30, 2026	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
VRDN Viridian Therapeutics, Inc.\DE this stock	$2.32B	-37.7%	-12.0%	—	17.2%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+11.3%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-4.8%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+544.3%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

216

% held: 120.5%
Reported: 2 of 217
Top holder: FMR LLC

Held Float

View

Held by Funds

Fund positions

264

View

Short & Settlement

Short Interest Falling

Shares short

19.5M

Days to cover: 15.7d
Change: -46.6K sh

View

Short Volume

Short vol %

65%

As of: Oct 2, 2026

Short Total

View

Fails to Deliver

FTD shares

Value: $93
As of: Sep 9, 2026

View

Off-Exchange

Off-exchange %

41.7%

Week of: Aug 31, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$348.2K

Buyers / Sellers: 0 / 1

Buyers Sellers

View

Financials

Revenue (FY)

$5.7M

Net income (FY): $-342.6M
EPS diluted: $-5.31

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Sep 8, 2026
This year: 17

View

Proposed Sales

Value

$348.2K

Shares: 14.2K
Filed: Aug 19, 2026

View

Exempt Offerings

Offering

$91.0M

Filed: Nov 6, 2020

View

Earnings & Events

Webcasts

Last webcast

Sep 8, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
VRDN	-5.2%	-15.5%	+31.1%	-5.8%	-37.7%
SPY	-0.2%	-0.5%	+12.2%	+0.9%	+12.9%
vs SPY	-5.0%	-15.1%	+18.9%	-6.7%	-50.5%

Key facts CIK 1590750 CUSIP 92790C104 13F (30d) 4 filings 4 filers Visit website Investor relations

VRDN · Viridian Therapeutics, Inc.\DE

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance